Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.47 |
| ▸ | ABAT | P80404 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4526183 | 0.87 | GPR35 (0.51) | POLBMAPK1ALDH1A1SMN1; SMN2TP53 | |
| SCHEMBL5913394 | 0.81 | ALDH1A1 (0.51) | POLBMAPK1ALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL1025776 | 0.81 | POLB (0.56) | POLBMAPK1ALDH1A1SMN1; SMN2TP53 | |
| SCHEMBL346032 | 0.81 | POLB (0.65) | POLBMAPK1ALDH1A1SMN1; SMN2TP53 | |
| SCHEMBL69585 | 0.80 | SNCA (0.62) | POLBMAPK1ALDH1A1SMN1; SMN2TP53 | |
| SCHEMBL11002820 | 0.80 | MAPK1 (0.60) | POLBMAPK1ALDH1A1SMN1; SMN2TP53 | |
| SCHEMBL30477507 | 0.80 | SNCA (0.62) | POLBMAPK1ALDH1A1SMN1; SMN2TP53 | |
| SCHEMBL5913449 | 0.80 | PDK1 (0.47) | POLBALDH1A1SMN1; SMN2MAPTNPSR1 | |
| SCHEMBL15156898 | 0.80 | TSHR (0.54) | POLBALDH1A1SMN1; SMN2TSHRGPR35 | |
| SCHEMBL5913237 | 0.80 | VCAM1 (0.54) | POLBALDH1A1MAPTKDM4EAPOBEC3G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036474-A1 | Quinazoline derivatives for use against cancer | PLE PATRICK | 2009-02-05 | — | — | US | disclosed |
| EP-1802608-A1 | QUINAZOLINE DERIVATIVES FOR USE AGAINST CANCER | AstraZeneca AB (SE) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006040526-A1 | QUINAZOLINE DERIVATIVES FOR USE AGAINST CANCER | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | disclosed |
| EP-0396642-B1 | ENZYME CONTROLLED RELEASE SYSTEM | POLAROID CORP (US) | 1994-05-11 | — | — | EP | disclosed |
| US-5112739-A | Quinone-methide elimination | POLAROID CORPORATION (US) | 1992-05-12 | — | — | US | disclosed |
| EP-0396642-A1 | ENZYME CONTROLLED RELEASE SYSTEM. | POLAROID CORP (US) | 1990-11-14 | — | — | EP | disclosed |
| WO-1990001558-A1 | ENZYME CONTROLLED RELEASE SYSTEM | POLAROID CORPORATION (US) | 1990-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036474-A1 | Quinazoline derivatives for use against cancer | AQP3, AQP1, F12 | POLB 2260/4885MAPK1 1135/4885ALDH1A1 2449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.